Single infusion of Carvykti delivered five-year treatment-free remissions in 50% of early-line multiple myeloma patients

Johnson & Johnson said a single infusion of Carvykti delivered five-year treatment-free remissions in 50% of patients with early-line relapsed/refractory multiple myeloma. The five-year overall survival rate was 69.2%, and median progression-free survival was 60.5 months.